News
-
-
-
PRESS RELEASE
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
TuHURA Biosciences, Inc. announces IFx-2.0 Phase 1b trial results accepted for poster presentation at 2024 ASCO Annual Meeting. Company to form new entity with Kintara Therapeutics, Inc. and focus on cancer vaccines and bi-functional ADCs -
-